Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5506950 | 0.63 | CHEK1 (0.50) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL13676237 | 0.63 | HTR6 (0.37) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL23657960 | 0.62 | CHEK1 (0.41) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL654875 | 0.62 | CHEK1 (0.38) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL28001390 | 0.61 | CHEK1 (0.37) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL6069967 | 0.60 | MAPT (0.36) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL15294999 | 0.59 | CHEK1 (0.41) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL6290912 | 0.59 | CHEK1 (0.41) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL656129 | 0.58 | MAPT (0.35) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL1669948 | 0.58 | MAPT (0.41) | MAPTALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040053966-A1 | Chemical derivatives and their application as antitelomerase agent | AVENTIS PHARMS S.A. | 2004-03-18 | — | — | US | disclosed |
| US-6645964-B1 | 1,3,5-Triazine compounds substituted with aromatic N-heterocycle; anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2003-11-11 | — | — | US | disclosed |
| EP-1244650-B1 | ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA SA (FR) | 2003-06-25 | — | — | EP | disclosed |
| EP-1244650-A1 | ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001040218-A1 | ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053966-A1 | Chemical derivatives and their application as antitelomerase agent | NTPCR, DPYD, NME1 | CHEK1 443/4885AURKA 1002/4885DAPK3 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.